Skip to main content

Table 1 Patients characteristics according to type of chemotherapy added to trastuzumab

From: Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

  Docetaxel (106) Vinorelbine (72) P
Median Age, years (range) 55 (33-73) 54 (29-81) 0.47
HER2 Status    0.05
   IHC 3+ 86 (81%) 66 (92%)  
   IHC 2+1 20 (19%) 6 (8%)  
ER positive2 50 (47%) 32 (44%) 0.63
PgR positive3 34 (32%) 22 (31%) 0.64
Initial disease Stage4    < 0.01
   I 12 (11%) 7 (10%)  
   II and III 71 (67%) 58 (80%)  
   IV 23 (22%) 6 (8%)  
Prior adjuvant/neoadjuvant chemotherapy 70 (66%) 55 (76%) 0.14
Prior exposure to anthracycline5 62 (58%) 50 (69%) 0.14
Prior exposure to taxanes5 16 (15%) 31 (43%) < 0.01
Prior endocrine therapy6 43 (40%) 35 (49%) 0.24
Median DFS in months (range)7 21 (0-136) 24 (0-146) 0.33
Sites of metastatic disease    
   Liver 58 (55%) 33 (46%) 0.24
   Lung 43 (41%) 18 (25%) 0.03
   Bone 46 (43%) 30 (42%) 0.82
   Soft-tissue/nodes 71 (67%) 37 (51%) 0.04
   Central nervous system 4 (4%) 3 (4%) 0.90
Visceral involvement (lung + liver + CNS) 82 (77%) 47 (65%) 0.08
Number metastatic sites    0.09
   1 31 (29%) 28 (39%)  
   2 30 (28%) 25 (35%)  
   ≥ 3 45 (42%) 19 (26%)